Skip to main content
. 2017 Jun 20;2017:7672485. doi: 10.1155/2017/7672485

Table 1.

Baseline demographics and ocular characteristics of participants (total of 70 eyes).

Total (n = 70 eyes) IVB group (n = 45 eyes) Control (n = 25 eyes) P value (IVB versus control)
Gender (male/female, number of patients) 56/14 38/7 18/7 0.212
Age (years) 58 ± 13 59 ± 10 57 ± 18 0.556
Causes of NVG, number (%)
 PDR 47 (67) 33 (73) 14 (56)
 CRVO 8 (11) 5 (11) 3 (12) 0.110
 OIS 12 (17) 7 (16) 5 (20)
Baseline IOP (mmHg) 40.5 ± 9.2 40.3 ± 9.7 41.0 ± 8.4 0.759
Baseline BCVA (LogMAR) 2.01 ± 1.11 1.96 ± 1.07 2.12 ± 1.20 0.556
Presence of NVA, number (%) 66 (94) 42 (93) 24 (96) 1.000
PAS extent, number (%)
 Less than 50% 46 (66) 35 (78) 11 (44) 0.004
 More than 50% 24 (34) 10 (22) 14 (56)
Preoperative PRP, number (%) 56 (80) 38 (84) 18 (72) 0.212
Postoperative follow-up (months) [range] 27 ± 15 [12–68] 26 ± 16 [12–68] 27 ± 14 [12–67] 0.721

IVB = intravitreal bevacizumab; NVG = neovascular glaucoma; PDR = proliferative diabetic retinopathy; CRVO = central retinal vein occlusion; OIS = ocular ischemic syndrome; IOP = intraocular pressure; BCVA = best-corrected visual acuity; MAR = minimal angle of resolution; NVA = neovascularization of angle; PAS = peripheral anterior synechiae; PRP = panretinal photocoagulation. Continuous variables are represented as mean ± standard deviation.